1702816-75-8

Basic information

• Product Name: PI3Kδ-IN-2
• Synonyms: YY-20394;PI3KδPI3K|A-IN-2;Linperlisib;PI3Kδ inhibitor 2;Linperlisib free base;Linperlisib (YY-20394);YY-20394;YY 20394;YY20394;Methanesulfonamide, N-[5-[6-fluoro-8-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-2-(4-morpholinyl)-4-quinazolinyl]-2-methoxy-3-pyridinyl]-
• CAS NO: 1702816-75-8
• Molecular Formula: C28H37FN6O5S
• Molecular Weight: 588.6939832
• Mol File: 1702816-75-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 742.4±70.0 °C(Predicted)
• Appearance: /
• Density: 1.355±0.06 g/cm3(Predicted)
• PKA: 5.81±0.50(Predicted)
• CAS DataBase Reference: PI3Kδ-IN-2(CAS DataBase Reference)
• NIST Chemistry Reference: PI3Kδ-IN-2(1702816-75-8)
• EPA Substance Registry System: PI3Kδ-IN-2(1702816-75-8)

Safety Data

• Hazardous Substances Data: 1702816-75-8(Hazardous Substances Data)

Usage

General Description

PI3Kδ-IN-2 is a specific inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) enzyme, which is involved in various cellular functions such as cell growth, proliferation, and survival. It functions by binding to the ATP-binding site of the PI3Kδ enzyme, inhibiting its activity and thereby halting the signaling pathways that it regulates. PI3Kδ-IN-2 has shown promise as a potential treatment for certain types of cancer and inflammatory diseases, as it targets the dysregulated PI3Kδ signaling that is often associated with these conditions. However, further research is needed to fully understand its effectiveness and potential side effects in a clinical setting.

Relevant articles and documents

FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF

Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3Kδ, and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.